Phenome‐Wide Association Study of Autoantibodies to Citrullinated and Noncitrullinated Epitopes in Rheumatoid Arthritis
Objective Patients with rheumatoid arthritis (RA) develop autoantibodies against a spectrum of antigens, but the clinical significance of these autoantibodies is unclear. Using a phenome‐wide association study (PheWAS) approach, we examined the association between autoantibodies and clinical subphen...
Saved in:
Published in | Arthritis & rheumatology (Hoboken, N.J.) Vol. 69; no. 4; pp. 742 - 749 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Wiley Subscription Services, Inc
01.04.2017
Wiley John Wiley and Sons Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Objective
Patients with rheumatoid arthritis (RA) develop autoantibodies against a spectrum of antigens, but the clinical significance of these autoantibodies is unclear. Using a phenome‐wide association study (PheWAS) approach, we examined the association between autoantibodies and clinical subphenotypes of RA.
Methods
This study was conducted in a cohort of RA patients identified from the electronic medical records (EMRs) of 2 tertiary care centers. Using a published multiplex bead assay, we measured 36 autoantibodies targeting epitopes implicated in RA. We extracted all International Classification of Diseases, Ninth Revision (ICD‐9) codes for each subject and grouped them into disease categories (PheWAS codes), using a published method. We tested for the association of each autoantibody (grouped by the targeted protein) with PheWAS codes. To determine significant associations (at a false discovery rate [FDR] of ≤0.1), we reviewed the medical records of 50 patients with each PheWAS code to determine positive predictive values (PPVs).
Results
We studied 1,006 RA patients; the mean ± SD age of the patients was 61.0 ± 12.9 years, and 79.0% were female. A total of 3,568 unique ICD‐9 codes were grouped into 625 PheWAS codes; the 206 PheWAS codes with a prevalence of ≥3% were studied. Using the PheWAS method, we identified 24 significant associations of autoantibodies to epitopes at an FDR of ≤0.1. The associations that were strongest and had the highest PPV for the PheWAS code were autoantibodies against fibronectin and obesity (P = 6.1 × 10−4, PPV 100%), and that between fibrinogen and pneumonopathy (P = 2.7 × 10−4, PPV 96%). Pneumonopathy codes included diagnoses for cryptogenic organizing pneumonia and obliterative bronchiolitis.
Conclusion
We demonstrated application of a bioinformatics method, the PheWAS, to screen for the clinical significance of RA‐related autoantibodies. Using the PheWAS approach, we identified potentially significant links between variations in the levels of autoantibodies and comorbidities of interest in RA. |
---|---|
Bibliography: | Drs. Liao and Sparks contributed equally to this work. Supported by the Rheumatology Research Foundation (Disease Targeted Pilot Grant) and the NIH (Harvard Clinical and Translational Science Center grant UL1‐TR‐001102 from the National Center for Advancing Translational Sciences). Dr. Liao's work was supported by the NIH (National Institute of Arthritis and Musculoskeletal and Skin Diseases [NIAMS] grant K08‐AR‐020657 and National Heart, Lung, and Blood Institute grant R01‐HL‐127118) and the Harold and Duval Bowen Fund. Dr. Sparks’ work was supported by the Rheumatology Research Foundation (Scientist Development Award) and the NIH (NIAMS grants L30‐AR‐066953 and K23‐AR‐069688). Drs. Hejblum and Tianxi Cai's work was supported by the NIH (National Human Genome Research Institute grant U54‐HG‐007963). Dr. Liu's work was supported by the Natural Science Foundation of China (grants 11322107 and 11431006). Dr. T. Tony Cai's work was supported in part by the NSF (grants DMS‐1208982 and DMS‐1403708) and the NIH (National Cancer Institute grant R01‐CA‐127334). ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 PMCID: PMC5378622 |
ISSN: | 2326-5191 2326-5205 2326-5205 2326-5191 |
DOI: | 10.1002/art.39974 |